MedPath

How Weekly Vitamin Treatment Affects Thinking in Kidney Patients on Dialysis

Phase 2
Conditions
Health Condition 1: N184- Chronic kidney disease, stage 4 (severe)
Registration Number
CTRI/2024/07/070810
Lead Sponsor
Meitra Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Yet Recruiting
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

1.Patients above 18 years

2.On MHD for CKD for more than three months

3.Patients who agree to give consent for the study

Exclusion Criteria

1.Patients with diagnosed dementia like

Alzheimer’s.

2.Patients with malignancy.

3.Patients who are unable to cooperate and

complete study.

4.Patients allergic to thiamine.

5.Patients who are already on thiamine

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The primary endpoint is the cognitive assessment with MOCA at the end of 24 weeksTimepoint: The primary endpoint is the cognitive assessment with MOCA at the end of 24 weeks
Secondary Outcome Measures
NameTimeMethod
1.The number of hospital admission days in the treatment and control groups at 24 weeks. <br/ ><br>2.Survival comparison between the treatment and control groups at 24 weeks of follow-up. <br/ ><br>3.The Quality of life in both groups at baseline and after 24 weeks <br/ ><br> <br/ ><br> <br/ ><br>Timepoint: 24 weeks
© Copyright 2025. All Rights Reserved by MedPath